3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
3
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Advanced Solid Tumor Cancer
1
Advanced Malignant Solid Tumors
1
Interventions
pembrolizumab
6
Nivolumab
3
budigalimab
2
Paclitaxel
2
Ipilimumab
2
Docetaxel
2
venetoclax
1
tislelizumab
1
talazoparib
1
spartalizumab
1
rovalpituzumab tesirine
1
regorafenib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine
1
epacadostat
1
durvalumab
1
cabozantinib
1
Platinum
1
Levoleucovorin
1
Leucovorin
1
Interleukin-2
1
IPI-549
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Everolimus
1
Cyclophosphamide
1
Clinical Trials, Phase II as Topic
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Clinical Trials, Phase II as Topic
×
Other solid neoplasm
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled